摘要
Adjuvant chemoradiotherapy,molecular targeted therapy,and immunotherapy are frequently employed to extend the survival of patients with advanced gastric cancer(GC).However,most of these treatments have toxic side effects,drug resistance,and limited improvements in survival and quality of life.Therefore,it is crucial to discover and develop new medications targeting GC that are highly effective and have minimal toxicity.In previous studies,the total terpene extract from the stem of Celastrus orbiculatus demonstrated anti-GC activity;however,the specific mechanism was unclear.Our research utilising coimmunoprecipitation-mass spectrometry(Co-IP-MS),polypyrimidine tract binding protein 1(ptbp1)clustered regularly interspaced short palindromic repeat-associated protein 9(Cas9)-knockout(KO)mouse model,tissue microarray,and functional experiments suggests that alpha actinin-4(ACTN4)could be a significant biomarker of GC.PTBP1 influences actin cytoskeleton restructuring in GC cells by interacting with ACTN4.Celastrus orbiculatus stem extract(COE)may directly target ACTN4 and affect the interaction between PTBP1 and ACTN4,thereby exerting anti-GC effects.
基金
financially supported by the National Natural Science Foundation of China(Grant Nos.:82274603 and 82104946)
the Natural Science Foundation of Jiangsu Province,China(Grant No.:BK20210817)
the Traditional Chinese Medicine Science and Technology Development Project of Jiangsu Province,China(Project code:QN202008)
the Young Scientific and Technological Talents Uplift Project of Jiangsu Association of Integrated Traditional Chinese and Western Medicine,China(Grant No.:JSZXTJ-2024-A05)
the Postgraduate Research&Practice Innovation Program of Jiangsu Province,China(Grant No.:KYCX21_3295)
the Yangzhou University Graduate Student International Academic Exchange Special Fund Project,China.Thanks for the Graphical abstract drawn。
作者简介
Zewen Chu,contributed equally to this work;Miao Zhu,contributed equally to this work;Corresponding author:Haibo Wang.E-mail addresses:whbosy@163.com;Corresponding author:Masataka Sunagawa.E-mail addresses:suna@med.showa-u.ac.jp;Corresponding author:Yanqing Liu.E-mail addresses:yzumpi@163.com。
